Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Head and Neck Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    December 2017
  1. CHUNG MK, Jung YH, Lee JK, Cho SY, et al
    CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma Through the Upregulation of Slug.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-0866.
    PubMed     Text format     Abstract available


    November 2017
  2. KRAFT IL, Akshintala S, Zhu YJ, Lei H, et al
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Clin Cancer Res. 2017 Nov 29. pii: 1078-0432.CCR-17-2101.
    PubMed     Text format     Abstract available


  3. WANG X, Beitler JJ, Huang W, Chen G, et al
    Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0345.
    PubMed     Text format     Abstract available


  4. FUKUSUMI T, Guo T, Sakai A, Ando M, et al
    The NOTCH4-HEY1 pathway induces epithelial mesenchymal transition in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1366.2017.
    PubMed     Text format     Abstract available


  5. ZHONG Q, Liu Z, Lin ZR, Hu ZD, et al
    The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.0352.2016.
    PubMed     Text format     Abstract available


  6. LIU X, Kumar M, Yang L, Molkentine DP, et al
    BAP1 is a novel target in HPV negative head and neck cancer.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1573.2017.
    PubMed     Text format     Abstract available


  7. LIN C, Zhang N, Wang Y, Wang Y, et al
    Functional Role of A Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis.
    Clin Cancer Res. 2017 Nov 3. pii: clincanres.1851.2017.
    PubMed     Text format     Abstract available


    October 2017
  8. SHAYAN G, Kansy BA, Gibson SP, Srivastava RM, et al
    A Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.0357.2017.
    PubMed     Text format     Abstract available


  9. NIEHR F, Eder T, Pilz T, Konschak R, et al
    Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2410.2017.
    PubMed     Text format     Abstract available


  10. YANG Q, Zhang MX, Zou X, Liu YP, et al
    A prognostic bio-model based on SQSTM1 and N stage identifies nasopharyngeal carcinoma patients at high risk of metastasis for additional induction chemotherapy.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1963.2017.
    PubMed     Text format     Abstract available


    September 2017
  11. WOOD O, Clarke J, Woo J, Mirza AH, et al
    Head and neck squamous cell carcinomas are characterized by a stable immune signature within the primary tumor over time.
    Clin Cancer Res. 2017 Sep 26. pii: clincanres.0373.2017.
    PubMed     Text format     Abstract available


  12. BIKTASOVA AK, Hajek M, Sewell AB, Gary CS, et al
    Demethylation therapy as a targeted treatment for human papilloma virus-associated head and neck cancer.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1438.2017.
    PubMed     Text format     Abstract available


    July 2017
  13. WHITESIDE TL
    Head and Neck Carcinoma Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1261.2017.
    PubMed     Text format     Abstract available


  14. MELL LK, Brumund KT, Daniels GA, Advani SJ, et al
    PHASE I TRIAL OF INTRAVENOUS ONCOLYTIC VACCINIA VIRUS (GL-ONC1) WITH CISPLATIN AND RADIOTHERAPY IN PATIENTS WITH LOCOREGIONALLY ADVANCED HEAD AND NECK CARCINOMA.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3232.2016.
    PubMed     Text format     Abstract available


    June 2017
  15. LU G, Little JV, Wang X, Zhang H, et al
    Detection of Head and Neck Cancer in Surgical Specimens Using Quantitative Hyperspectral Imaging.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.0906.2017.
    PubMed     Text format     Abstract available


    May 2017
  16. OZAWA H, Ranaweera R, Izumchenko E, Makarev E, et al
    SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells.
    Clin Cancer Res. 2017 May 18. pii: clincanres.1686.2016.
    PubMed     Text format     Abstract available


  17. SKINNER HD, Giri U, Yang LP, Kumar M, et al
    Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
    Clin Cancer Res. 2017 May 5. doi: 10.1158/1078-0432.CCR-16-2586.
    PubMed     Text format     Abstract available


    April 2017
  18. ROSENTHAL E, Moore L, Tipirneni K, de Boer E, et al
    Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.2968.2016.
    PubMed     Text format     Abstract available


  19. SALOURA V, Fatima A, Zewde M, Kiyotani K, et al
    Characterization of the tumor T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2017 Apr 25. pii: clincanres.0103.2017.
    PubMed     Text format     Abstract available


  20. LUDWIG S, Floros T, Theodoraki MN, Hong CS, et al
    Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.2819.2016.
    PubMed     Text format     Abstract available


    March 2017
  21. ZHANG S, Zhang B, Tian J, Dong D, et al
    Radiomics features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.2910.2016.
    PubMed     Text format     Abstract available


    February 2017
  22. HSU DS, Hwang WL, Yuh CH, Chu CH, et al
    Lymphotoxin-beta interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer.
    Clin Cancer Res. 2017 Feb 14. pii: clincanres.1955.2016.
    PubMed     Text format     Abstract available


    December 2016
  23. BRAND TM, Hartmann S, Bhola NE, Peyser ND, et al
    Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2203.2016.
    PubMed     Text format     Abstract available


  24. MUHAMMAD N, Bhattacharya S, Steele R, Phillips NJ, et al
    Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Dec 13. pii: clincanres.2811.2016.
    PubMed     Text format     Abstract available


    October 2016
  25. KERK S, Finkel K, Pearson AT, Warner K, et al
    5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Oct 25. pii: clincanres.1834.2016.
    PubMed     Text format     Abstract available


  26. YAMAMURA K, Baba Y, Nakagawa S, Mima K, et al
    Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


    September 2016
  27. MANCIKOVA V, Montero-Conde C, Perales-Paton J, Fernandez AF, et al
    Multilayer OMIC data in medullary thyroid carcinoma identifies the STAT3 pathway as a potential therapeutic target in RETM918T tumors.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0947.2016.
    PubMed     Text format     Abstract available


    August 2016
  28. SRIVASTAVA RM, Trivedi S, Concha-Benavente F, Gibson SP, et al
    CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients.
    Clin Cancer Res. 2016 Aug 5. pii: clincanres.0879.2016.
    PubMed     Text format     Abstract available


    July 2016
  29. ZHANG JX, Chen ZH, Xu Y, Chen JW, et al
    Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem-cell-like Phenotype via Dysregulation of PITX2.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0414.2016.
    PubMed     Text format     Abstract available


  30. HARTMANN S, Bhola NE, Grandis JR
    HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
    Clin Cancer Res. 2016 Jul 1. pii: clincanres.0951.2016.
    PubMed     Text format     Abstract available


    June 2016

  31. Correction: Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients.
    Clin Cancer Res. 2016;22:3118.
    PubMed     Text format    


    May 2016
  32. TRIVEDI S, Srivastava RM, Concha-Benavente F, Ferrone S, et al
    Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients.
    Clin Cancer Res. 2016 May 23. pii: clincanres.2971.2015.
    PubMed     Text format     Abstract available


    April 2016
  33. CHAU NG, Hammerman PS
    Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon.
    Clin Cancer Res. 2016 Apr 29. pii: clincanres.0582.2016.
    PubMed     Text format     Abstract available


  34. ZHANG Y, Koneva LA, Virani S, Arthur AE, et al
    Subtypes of HPV-positive head and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures.
    Clin Cancer Res. 2016 Apr 18. pii: clincanres.0323.2016.
    PubMed     Text format     Abstract available


  35. ZUMSTEG ZS, Morse N, Krigsfeld G, Gupta G, et al
    Taselisib (GDC-0032), a Potent beta-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Clin Cancer Res. 2016;22:2009-19.
    PubMed     Text format     Abstract available


  36. SKINNER HD, Giri U, Yang L, Woo SH, et al
    Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV negative head and neck cancer.
    Clin Cancer Res. 2016 Apr 1. pii: clincanres.2785.2015.
    PubMed     Text format     Abstract available


  37. GRANDIS J
    HER2 and HER3 in HPV+ and HPV- HNSCC--Response.
    Clin Cancer Res. 2016;22:1826.
    PubMed     Text format    


  38. MACHIELS JP, Galot R, Schmitz S
    HER2 and HER3 in HPV+ and HPV- HNSCC--Letter.
    Clin Cancer Res. 2016;22:1825.
    PubMed     Text format    


    March 2016
  39. CHEN P, Hu T, Liang Y, Li P, et al
    Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway through ATF4-CHOP-DR5 Axis in Human Esophageal Cancer Cells.
    Clin Cancer Res. 2016 Mar 16. pii: clincanres.2254.2015.
    PubMed     Text format     Abstract available


  40. KOOLE K, Brunen D, van Kempen PM, Noorlag R, et al
    FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.1874.2015.
    PubMed     Text format     Abstract available


    February 2016
  41. COGHILL AE, Bu W, Nguyen H, Hsu WL, et al
    High levels of antibody that neutralize B-cell infection of Epstein-Barr virus and that bind EBV gp350 are associated with a lower risk of nasopharyngeal carcinoma.
    Clin Cancer Res. 2016 Feb 26. pii: clincanres.2299.2015.
    PubMed     Text format     Abstract available


  42. LEE Y, Shin JH, Longmire M, Wang H, et al
    CD44+ cells in head and neck squamous cell carcinoma suppress T cell-mediated immunity by selective constitutive and inducible expression of PD-L1.
    Clin Cancer Res. 2016 Feb 10. pii: clincanres.2665.2015.
    PubMed     Text format     Abstract available


  43. MITANI Y, Liu B, Rao PH, Borra VJ, et al
    Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
    Clin Cancer Res. 2016;22:725-33.
    PubMed     Text format     Abstract available


  44. VASSILAKOPOULOU M, Avgeris M, Velcheti V, Kotoula V, et al
    Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2016;22:704-13.
    PubMed     Text format     Abstract available


    January 2016
  45. CHAU NG, Li YY, Jo VY, Rabinowits G, et al
    Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.2314.2015.
    PubMed     Text format     Abstract available


    December 2015
  46. ROTHENBERG SM, Daniels GH, Wirth LJ
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.
    Clin Cancer Res. 2015;21:5640-5641.
    PubMed     Text format    


  47. HUILLARD O, Tenenbaum F, Clerc J, Goldwasser F, et al
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Letter.
    Clin Cancer Res. 2015;21:5639.
    PubMed     Text format    


    November 2015
  48. ROMICK-ROSENDALE LE, Hoskins EE, Privette Vinnedge LM, Foglesong GD, et al
    Defects in the Fanconi anemia pathway in head and neck cancer cells stimulate tumor cell invasion through DNA-PK and Rac1 signaling.
    Clin Cancer Res. 2015 Nov 24. pii: clincanres.2209.2015.
    PubMed     Text format     Abstract available


    October 2015
  49. SWIERNIAK M, Wojcicka A, Czetwertynska M, Dlugosinska J, et al
    Association Between GWAS-derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1746.2015.
    PubMed     Text format     Abstract available


    August 2015
  50. NAIR A, Lemery SJ, Yang J, Marathe A, et al
    FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Aug 31. pii: clincanres.1377.2015.
    PubMed     Text format     Abstract available


  51. SCHLUMBERGER M, Jarzab B, Cabanillas ME, Robinson BG, et al
    A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC).
    Clin Cancer Res. 2015 Aug 26. pii: clincanres.1127.2015.
    PubMed     Text format     Abstract available


    June 2015
  52. CASAK SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, et al
    FDA Approval Summary: Ramucirumab for Gastric Cancer.
    Clin Cancer Res. 2015 Jun 5. pii: clincanres.0600.2015.
    PubMed     Text format     Abstract available


  53. JURIC D, Dienstmann R, Cervantes A, Hidalgo M, et al
    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
    Clin Cancer Res. 2015;21:2462-70.
    PubMed     Text format     Abstract available


    May 2015
  54. MEHTA A, Zhang L, Boufraqech M, Liu-Chittenden Y, et al
    Inhibition of survivin with YM155 induces durable tumor response in anaplastic thyroid cancer.
    Clin Cancer Res. 2015 May 5. pii: clincanres.3251.2014.
    PubMed     Text format     Abstract available


    April 2015
  55. MACDONALD AJ, Johns N, Stephens N, Greig C, et al
    Habitual Myofibrillar Protein Synthesis Is Normal in Patients with Upper GI Cancer Cachexia.
    Clin Cancer Res. 2015;21:1734-40.
    PubMed     Text format     Abstract available


    December 2014
  56. ROTHENBERG SM, McFadden DG, Palmer EL, Daniels GH, et al
    Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
    Clin Cancer Res. 2014 Dec 30. pii: clincanres.2915.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: